BioScience Ventures Group AG

The BioScience Ventures Group (BSVG) is an association of experienced business angels focused exclusively on investments in early-stage life-science companies. Investment size varies from 0.2 to 0.5 Mio. Euro per investment round. BSVG consists furthermore of an experienced team with medical and pharmacological background specialized in drug development, the design of preclinical and clinical studies especially in the field of Biologics as for example antibodies or proteins.

Nicole Wistuba

Managing Director

5 past transactions

Nano4Imaging

Venture Round in 2013
Nano4Imaging produces and uses medical devices and implants visible for medical interventions to monitor their function (e.g under MRI). N4I’s products MRWire and MagnaFy are used for navigation to treat cardiovascular diseases and for radiotherapy.

MagnaMedics

Series B in 2011
MagnaMedics engineers and produces magnetic nano- and microparticles that are used in medical devices, drug delivery tools and diagnostic kits. Diagnostic kits are used for determination of biomarkers in body fluids; the company focuses on proteomics and more specifically on high-quantity isolation of proteins as well as on research customers active in high-throughput screening of biomarkers.
APEPTICO is an innovative biotech company that develops new peptide-based medicinal drugs for the therapeutic and prophylactic treatment of severe and chronic diseases.

Diaferon

Seed Round in 2007
Diaferon is a biotechnology company developing a drug delivery system to control the release and distribution of therapeutic particles.

ugichem

Series B in 2007
ugichem is an innovative biotech company based on unique chemistry and focused on the development of novel antisense drugs. Their mission is to turn antisense into therapeutics.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.